Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
Administration, Intravenous
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Breast Neoplasms
/ drug therapy
Central Nervous System Neoplasms
/ drug therapy
Drug Administration Schedule
Drug Dosage Calculations
Female
Humans
Methotrexate
/ therapeutic use
Middle Aged
Neoplasm Metastasis
Survival Analysis
Breast
Central nervous system
Chemotherapy
Methotrexate
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
01 Nov 2019
01 Nov 2019
Historique:
received:
25
03
2019
accepted:
09
10
2019
entrez:
3
11
2019
pubmed:
5
11
2019
medline:
21
3
2020
Statut:
epublish
Résumé
Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patients with central nervous system (CNS) metastases of breast cancer. Twenty-two patients with CNS metastases treated by MTX (3 g/m2) between April 2004 and October 2009 were enrolled. Clinical response rate, time to progression (TTP), overall survival (OS), and safety were assessed. In terms of brain metastases, 2 patients (9%) achieved a partial response, 10 patients (45%) had disease stabilization, and 10 patients (45%) had disease progression. In others metastatic sites, 7 patients (39%) achieved a disease stabilization, and 11 patients (61%) had disease progression. TTP and OS were 2.1 (95%CI 1.4-2.9) and 6.3 (95%CI 1.8-10) months, respectively. High-dose MTX demonstrated a moderate activity at 3 g/m
Sections du résumé
BACKGROUND
BACKGROUND
Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patients with central nervous system (CNS) metastases of breast cancer.
METHODS
METHODS
Twenty-two patients with CNS metastases treated by MTX (3 g/m2) between April 2004 and October 2009 were enrolled. Clinical response rate, time to progression (TTP), overall survival (OS), and safety were assessed.
RESULTS
RESULTS
In terms of brain metastases, 2 patients (9%) achieved a partial response, 10 patients (45%) had disease stabilization, and 10 patients (45%) had disease progression. In others metastatic sites, 7 patients (39%) achieved a disease stabilization, and 11 patients (61%) had disease progression. TTP and OS were 2.1 (95%CI 1.4-2.9) and 6.3 (95%CI 1.8-10) months, respectively.
CONCLUSION
CONCLUSIONS
High-dose MTX demonstrated a moderate activity at 3 g/m
Identifiants
pubmed: 31675937
doi: 10.1186/s12885-019-6228-6
pii: 10.1186/s12885-019-6228-6
pmc: PMC6823971
doi:
Substances chimiques
Antineoplastic Agents
0
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1029Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):795-803
pubmed: 10098435
Future Oncol. 2018 Feb;14(4):391-407
pubmed: 29345149
Neurotherapeutics. 2009 Jul;6(3):598-603
pubmed: 19560748
Clin Cancer Res. 2009 Feb 15;15(4):1452-9
pubmed: 19228746
Curr Treat Options Oncol. 2006 Nov;7(6):479-89
pubmed: 17032560
Cancer. 1983 Dec 15;52(12):2349-54
pubmed: 6640506
Curr Probl Cancer. 2017 Sep - Oct;41(5):355-370
pubmed: 28779849
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Cancer Metastasis Rev. 2007 Dec;26(3-4):635-43
pubmed: 17717635
J Neurooncol. 2007 Dec;85(3):311-7
pubmed: 17557136
Oncologist. 2007 Jul;12(7):884-98
pubmed: 17673619
J Neurooncol. 2006 Jul;78(3):255-60
pubmed: 16344918
J Clin Oncol. 1998 Apr;16(4):1561-7
pubmed: 9552066
Eur J Cancer. 2009 Nov;45(16):2792-8
pubmed: 19643597
Lancet Oncol. 2013 Jan;14(1):64-71
pubmed: 23122784
Br J Cancer. 2009 Mar 24;100(6):894-900
pubmed: 19240719
J Clin Oncol. 2004 Sep 1;22(17):3608-17
pubmed: 15337811
South Med J. 1988 Sep;81(9):1109-12
pubmed: 3420442
Br J Cancer. 2012 Jan 3;106(1):25-31
pubmed: 22127284
Cancer. 2003 Jun 15;97(12):2972-7
pubmed: 12784331
Lancet Oncol. 2016 Jul;17(7):976-983
pubmed: 27267608